We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nonfasting Screening Tests Evaluated for Dysglycemia

By LabMedica International staff writers
Posted on 19 Jan 2012
The performance of nonfasting tests to screen children for dysglycemia, either prediabetic or diabetic, has been appraised. More...


The screening tests included a random glucose test, fructosamine and the glycosalated hemoglobin test, HbA1c, following a formal glucose tolerance test (OGTT) performed on a previous visit.

Scientists at the University of Michigan (Ann Arbor, MI, USA) conducted a cross-sectional study of 254 overweight or obese children aged 10-17 years. Subjects came for two visits to a clinical research unit. They arrived fasting on the first visit and a glucose tolerance test and HbA1c and fructosamine testing were performed. For the second visit, they arrived nonfasting and had a random plasma glucose, a one hour 50-gram nonfasting glucose challenge test (1-h GCT), and urine dipstick performed. The primary end point was dysglycemia, that is a fasting plasma glucose of greater than 99 mg/dL or a two-hour postglucose greater than139 mg/dL. Approximately 50% of the children were female, 59% were white, and 30% were black.

The results of the study showed that there were 99 (39%) cases of prediabetes and 3 (1.2%) cases of diabetes. Urine dipstick, HbA1c, and fructosamine displayed poor discrimination for identifying children with dysglycemia. Both random glucose and 1-h GCT had better levels of test discrimination than HbA1c or fructosamine.

Glucose, fructosamine, and HbAlc were all measured using the Cobas Mira Plus Chemistry Analyzer (Roche; Basle, Switzerland). The urine dipstick test was performed using Chemstrip 10 strips also manufactured by Roche.

The authors concluded that they found reasonable test performance for the 1-h GCT and the random glucose, having systematically evaluated a variety of nonfasting screening tests used in the clinical setting for identifying dysglycemia in a population of overweight and obese adolescents, In contrast, test performance for HbAlc, fructosamine, and urinalysis was poor. Their findings have direct relevance for future recommendations for screening and diagnosis of dysglycemia among overweight and obese children and adolescents. The study was published the December 2011 issue of the journal Diabetes Care.

Related Links:

University of Michigan
Roche



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.